US-based medical technology company Osteoboost Health has announced the availability of Osteoboost, a wearable prescription medical device designed to combat low bone density, across the country.
This at-home system device claims to deliver targeted vibration therapy to the hips and spine areas, and those most susceptible to osteoporotic fractures.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Calibrated for bone health, the device’s patented vibration technology is claimed to be validated clinically in a randomised trial to slow the vertebral bone density and strength loss.
The US Food and Drug Administration (FDA) has designated Osteoboost as a breakthrough device, and it was approved via the de novo pathway.
According to the company, results from a double-blinded, placebo-controlled clinical trial at the University of Nebraska Medical Center, US, showed that the device slowed the loss of bone density and strength in postmenopausal women with osteopenia who used the device at least thrice a week and experienced 85% and 83% minimisations in spine bone density and strength loss, respectively.
The women also found a 55% minimisation in the loss of hip bone density.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataOsteoboost Health CEO Laura Yecies said: “The longevity conversation is everywhere, but people rarely mention bone health even though it is fundamental to ageing with confidence.
“Osteoboost empowers people to lead longer, stronger, and more active lives. And while the belt is sophisticated medical technology rigorously tested and validated for efficacy, the treatment is so easy – 30 minutes a day of gentle vibration therapy that can be done while walking, cooking, or other daily activities.”
For increased accessibility, Osteoboost Health has collaborated with virtual care platform, Beluga Health, to offer online prescription consultations.
This service provides individuals with the option to obtain a prescription from home via their physician or an online platform, thus eliminating delays and facilitating rapid access to the device.
In July 2024, the company acquired an online exercise and fall prevention platform, Wellen, for women with low bone density.
